BRIEF-Seres Therapeutics completes enrollment in early stage study of ulcerative colitis drug
June 05, 2017 at 07:35 AM EDT
* Seres Therapeutics announces completion of enrollment for ser-287 phase 1b study in patients with ulcerative colitis